MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8.
On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years. For these recommendations, ACIP considered information on vaccine efficacy (including data available since October 2009, on prevention of grade 2 or 3 anal intraepithelial neoplasia [AIN2/3], a precursor of anal cancer), vaccine safety, estimates of disease and cancer resulting from HPV, cost-effectiveness, and programmatic considerations. The evidence for HPV4 vaccination of males was evaluated using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methods.
2011 年 10 月 25 日，免疫实践咨询委员会（ACIP）建议在 11 或 12 岁的男性中常规使用四价人乳头瘤病毒（HPV）疫苗（HPV4；默克公司的佳达修）。ACIP 还建议对以前未接种过或未完成 3 剂系列接种的 13 至 21 岁男性接种 HPV4；22 至 26 岁的男性可以接种疫苗。这些建议取代了 2009 年 10 月 ACIP 的指导意见，即 HPV4 可用于 9 至 26 岁的男性。对于这些建议，ACIP 考虑了疫苗功效（包括自 2009 年 10 月以来可用的数据，预防 2 级或 3 级肛门上皮内瘤变[AIN2/3]，肛门癌的前身）、疫苗安全性、HPV 导致的疾病和癌症的估计、成本效益和计划考虑因素。使用推荐分级、评估、开发和评估（GRADE）方法评估了 HPV4 疫苗接种男性的证据。
